This clinical trial is focused on studying treatments for subfertility, a condition where individuals have difficulty conceiving. The study will compare two approaches to help women who are expected to have a low response to ovarian stimulation, which is a process used in assisted reproductive technology (ART) to encourage the ovaries to produce eggs. The first approach involves using a medication called corifollitropin alfa, known by the brand name Elonva, which is a solution for injection. The second approach involves up to three modified natural cycles, which are less intensive treatments that aim to support the natural menstrual cycle.
The purpose of the study is to compare the chances of achieving at least one good quality blastocyst, which is an early stage of embryo development, after using corifollitropin alfa versus the modified natural cycles. A blastocyst is considered good quality if it meets specific criteria known as the Gardner score. Participants in the study will receive either the medication or a placebo, and their progress will be monitored over a period of time to assess the outcomes.
Throughout the study, participants will receive injections of the medication under the skin, a method known as subcutaneous use. Other medications involved in the study include ganirelix (Orgalutran), choriogonadotropin alfa (Ovitrelle), and follitropin beta (Puregon), all of which are also solutions for injection. The study aims to provide valuable insights into the effectiveness of these treatments in improving the chances of conception for women with subfertility.
Belgium 
